7,370 IQVIA Holdings Inc. $IQV Shares Sold by One Way Holdings LLC

One Way Holdings LLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 6.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 99,017 shares of the medical research company’s stock after selling 7,370 shares during the period. IQVIA makes up approximately 1.2% of One Way Holdings LLC’s portfolio, making the stock its 26th largest position. One Way Holdings LLC owned 0.06% of IQVIA worth $26,621,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. North Dakota State Investment Board lifted its stake in IQVIA by 0.8% in the third quarter. North Dakota State Investment Board now owns 5,063 shares of the medical research company’s stock worth $1,361,000 after acquiring an additional 40 shares during the last quarter. Apella Capital LLC raised its stake in IQVIA by 4.7% in the third quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock valued at $319,000 after buying an additional 55 shares in the last quarter. Breakwater Capital Group raised its stake in IQVIA by 3.2% in the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after buying an additional 64 shares in the last quarter. Fortitude Family Office LLC lifted its holdings in IQVIA by 17.2% during the 3rd quarter. Fortitude Family Office LLC now owns 443 shares of the medical research company’s stock worth $119,000 after buying an additional 65 shares during the last quarter. Finally, First Growth Capital LLC lifted its holdings in IQVIA by 3.2% during the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after buying an additional 68 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on IQV shares. JPMorgan Chase & Co. increased their price objective on IQVIA from $295.00 to $325.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. TD Cowen upped their price target on IQVIA from $288.00 to $307.00 and gave the company a “buy” rating in a report on Thursday. HSBC raised their price objective on shares of IQVIA from $280.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, September 1st. BMO Capital Markets boosted their price objective on shares of IQVIA from $270.00 to $305.00 in a research report on Monday, October 19th. Finally, Truist Financial upped their target price on shares of IQVIA from $329.00 to $346.00 and gave the company a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $294.21.

IQVIA Stock Down 0.1%

IQVIA stock opened at $266.93 on Monday. The stock’s 50 day moving average price is $266.22 and its 200 day moving average price is $210.41. The company has a market cap of $43.99 billion, a PE ratio of 32.43, a price-to-earnings-growth ratio of 2.38 and a beta of 1.16. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $284.50.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. The company had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. IQVIA’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same quarter last year, the company earned $3.00 earnings per share. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the transaction, the insider directly owned 10,890 shares in the company, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.